Mark Soberman becomes president of ACCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mark Soberman, was elected as the 2017-2018 President of the Association of Community Cancer Centers during its annual meeting March 31.

A thoracic surgeon and thoracic oncologist, Soberman is the medical director, Oncology Service Line and chief physician executive, Monocacy Health Partners at Frederick Regional Health System.

Soberman has been an active member of ACCC, serving on the executive committee of the board of trustees and as President-Elect (2016-2017).

He is a reviewer for the Annals of Thoracic Surgery and an active member of numerous organizations, including the Society of Thoracic Surgeons, the Southern Thoracic Surgical Association, the General Thoracic Surgical Club, the American Association for Physician Leadership, the American College of Healthcare Executives, and the American Society of Clinical Oncology.

Previously, Soberman served as vice-chair of the Department of Surgery; director, Section of Thoracic Oncology; and director, Section of Thoracic Surgery at MedStar Washington Hospital Center. Soberman has held leadership positions as Director, Division of Thoracic S urgery at Georgetown University Hospital, and Director, Section of Thoracic Surgery at Sibley Memorial Hospital.

His academic appointments include clinical associate professor of surgery at Georgetown University School of Medicine and Clinical Assistant Professor of Surgery at George Washington University School of Medicine.

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login